Anthera Pharmaceuticals (ANTH) : 4 analysts are covering Anthera Pharmaceuticals (ANTH) and their average rating on the stock is 1, which is read as a Strong Buy. 4 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 4, which recommends a Sell affirms that they expect a large upside in the stock from the current levels.
Anthera Pharmaceuticals (ANTH) : 4 investment research analysts covering Anthera Pharmaceuticals (ANTH) have an average price target of $10.75 for the near short term. The highest target price given by the Brokerage Firm to the stock is $14 and the lowest target is $9 for the short term. Analysts expect the variance to be within $2.22 of the average price.
Anthera Pharmaceuticals, Inc. has dropped 5.85% in the last five trading days, however, the shares have posted positive gains of 4.89% in the last 4 weeks. Anthera Pharmaceuticals, Inc. has dropped 10.06% during the last 3-month period . Year-to-Date the stock performance stands at -30.6%. Anthera Pharmaceuticals (NASDAQ:ANTH): stock turned positive on Tuesday. Though the stock opened at $3.23, the bulls momentum made the stock top out at $3.28 level for the day. The stock recorded a low of $3.12 and closed the trading day at $3.22, in the green by 0.94%. The total traded volume for the day was 610,796. The stock had closed at $3.19 in the previous days trading.
Anthera Pharmaceuticals Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. The Companys primary Phase 3 product candidate blisibimod targets elevated levels of Bcell activating factor (BAFF) which has been associated with a variety of Bcell mediated autoimmune diseases including systemic lupus erythematosus or lupus IgA nephropathy lupus nephritis multiple myeloma and others. The Companys second product candidate Sollpura (liprotamase) is a Phase III investigational pancreatic enzyme replacement therapy (PERT) intended for the treatment of patients with exocrine pancreatic insufficiency (EPI) often seen in patients with cystic fibrosis and other conditions.